Abstract

Internal and external HDFCCC Leadership and Advisory Groups provide a robust mechanism for evaluating Center-wide priorities and activities, reviewing individual programs and shared resources, and providing an infrastructure to carry out responses to review processes such as those described above. Through these various forums, Ashworth has connections to receive feedback from and provide feedback to UCSF research and clinical leadership, peers in other research and clinical departments, HDFCCC executive leadership, HDFCCC members, CCSG components, members of the catchment area community, and leaders from other institutions and cancer centers. The HDFCCC leadership groups and advisory groups include: (1) the Executive Leadership Group; (2) the Senior Leadership Group; (3) the Scientific Leadership Group; (4) the Cancer Center Clinical Research Oversight Committee; (5) the Cancer Clinical Governance Board; (6) Research Program Meetings; (7) the Internal Advisory Board; (8) the Community Advisory Board; and (9) the External Advisory Board.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-21
Application #
9965781
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118

  Publications

Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28

Showing the most recent 10 out of 192 publications